Key facts
- This page summarizes James Healy's Form 4 filing for ArriVent Biopharma, Inc. (AVBP).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 31 Jan 2024, 16:10.
James Healy - 30 Jan 2024 Form 4 Insider Report for ArriVent Biopharma, Inc. (AVBP)
- Reporting relationship
- Director
- Issuer ticker
- AVBP
- Reported as of
- 30 Jan 2024
- Net transaction value
- +$7,999,992
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2024, 16:10:47 UTC
- Prior SEC filing
- 30 Jan 2024
- Next SEC filing
- 18 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Kastenmayer, Attorney-in-Fact for James Healy
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James Healy filed Form 4 for ArriVent Biopharma, Inc. (AVBP) on 31 Jan 2024.
Change
- Previous filing in this sequence was filed on 30 Jan 2024.
- Current net transaction value: +$7,999,992.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVBP
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,252,308
- Change %
- Price
- Shares after
- 1,252,308
- Date
- 30 Jan 2024
- Ownership
- Sofinnova Venture Partners XI, L.P.
- Footnotes
- F1, F2
AVBP
transaction
Common Stock
Purchase
- Transaction value
- $7,999,992
- Shares
- +444,444
- Change %
- +35%
- Price
- $18.00*
- Shares after
- 1,696,752
- Date
- 30 Jan 2024
- Ownership
- Sofinnova Venture Partners XI, L.P.
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVBP
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,252,308
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 30 Jan 2024
- Ownership
- Sofinnova Venture Partners XI, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 1,252,308
- Exercise price
- Footnotes
- F1, F2, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-15.21 basis.
Footnote F2
The shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
Footnote F3
Reflects shares purchased in the Issuer's initial public offering.
Footnote F4
The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.
Footnote F5
Not applicable.